Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $8.29 Consensus PT from Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $8.29.

A number of brokerages have commented on VTYX. HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research report on Tuesday, October 15th. Canaccord Genuity Group lowered their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Wells Fargo & Company dropped their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $2.15 on Monday. The business has a 50-day moving average of $2.25 and a 200-day moving average of $2.92. The company has a market capitalization of $151.94 million, a price-to-earnings ratio of -0.77 and a beta of 0.36. Ventyx Biosciences has a 1 year low of $1.79 and a 1 year high of $15.81.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. As a group, sell-side analysts anticipate that Ventyx Biosciences will post -2.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTYX. Farallon Capital Management LLC bought a new stake in Ventyx Biosciences during the 1st quarter valued at $17,435,000. Deerfield Management Company L.P. Series C increased its position in shares of Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after acquiring an additional 2,287,570 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Ventyx Biosciences by 944.4% in the 1st quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock worth $11,903,000 after acquiring an additional 1,956,923 shares during the last quarter. First Light Asset Management LLC bought a new position in Ventyx Biosciences in the 1st quarter valued at about $3,437,000. Finally, Ikarian Capital LLC boosted its stake in Ventyx Biosciences by 8,483.8% during the 1st quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock valued at $2,792,000 after purchasing an additional 501,733 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.